Antiretroviral Therapy during Long-term Surgical Care: ‘Exploring Difficult Cases in HIV Clinics’ of the Korean Society for AIDS Conference in 2023

키워드

참고문헌 (67)

1. Katz IT, "Improved life expectancy of people living with HIV : who is left behind?", Lancet HIV, 4, pp.e324~e326 (2017)
2. Trickey A, "Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America : a collaborative analysis of cohort studies", Lancet HIV, 10, pp.e295~e307 (2023)
3. Mahy M, "Increasing trends in HIV prevalence among people aged 50 years and older : evidence from estimates and survey data", AIDS, 28(Suppl 4), pp.S453~S459 (2014)
4. Autenrieth CS, "Global and regional trends of people living with HIV aged 50 and over : Estimates and projections for 2000-2020", PLoS One, 13, pp.e0207005~ (2018)
5. Lee M, "Possibility of decreasing incidence of human immunodeficiency virus infection in Korea", Infect Chemother, 55, pp.451~459 (2023)
6. Kim JH, "Trends of age-related non-communicable diseases in people living with HIV and comparison with uninfected controls : a nationwide population-based study in South Korea", HIV Med, 22, pp.824~833 (2021)
7. Jespersen NA, "The burden of non-communicable diseases and mortality in people living with HIV(PLHIV)in the pre-, early-and late-HAART era", HIV Med, 22, pp.478~490 (2021)
8. Bae JY, "Comparison of three cardiovascular risk scores among HIV-infected patients in Korea : The Korea HIV", AIDS cohort study, 2022, pp.54, 409~418
9. Park S, "The role of age in subclinical atherosclerosis in Asian people living with human immunodeficiency virus", Infect Chemother, 54, pp.308~315 (2022)
10. Jung H, "Mortality after acute coronary syndrome in human immunodeficiency virus infection with optimal adherence : a nationwide study", Infect Chemother, 55, pp.471~478 (2023)
11. Seong H, "Assessment of disease burden and immunization rates for vaccine-preventable diseases in people living with HIV : the Korea HIV", AIDS cohort study, 2023, pp.55, 441~450
12. Duffy M, "Non-communicable diseases and HIV care and treatment : models of integrated service delivery", Trop Med Int Health, 22, pp.926~937 (2017)
13. Lee JA, "Identifying the unmet medical needs of HIV-positive subjects in Korea : results of a nationwide online survey", Infect Chemother, 55, pp.397~402 (2023)
14. Choi JP, "The story and implications of the Korean health care facility counseling project on people living with HIV", Infect Chemother, 55, pp.167~178 (2023)
15. Kim JH, "Implementation of a nurse-delivered cognitive behavioral therapy for adherence and depression of people living with HIV in Korea", Infect Chemother, 54, pp.733~743 (2022)
16. Gahagan JV, "Colorectal surgery in patients with HIV and AIDS : trends and outcomes over a 10-year period in the USA", J Gastrointest Surg, 20, pp.1239~1246 (2016)
17. "Guidelines for the use of antiretroviral agents in adults and adolescents with HIV"[URL]
18. "Guidelines Version 12.0 October 2023"[URL]
19. Seong H, "Rate of and risk factors for loss to follow up in HIV-infected patients in Korea : the Korea HIV", AIDS cohort study, 2023, pp.55, 69~79
20. Arts EJ, "Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription", Antimicrob Agents Chemother, 40, pp.527~540 (1996)
21. Oh SM, "Resistance trends of antiretroviral agents in people with human immunodeficiency virus in Korea, 2012-2020", Infect Chemother, 55, pp.328~336 (2023)
22. Holkmann Olsen C, "Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death", HIV Med, 8, pp.96~104 (2007)
23. Kousignian I, "Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency", Clin Infect Dis, 46, pp.296~304 (2008)
24. Danel C, "CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa(Trivacan ANRS 1269 trial) : a randomised trial", Lancet, 367, pp.1981~1989 (2006)
25. DART Trial Team, "Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells", microl, 2008, pp.22, 237~247
26. Strategies for Management of Antiretroviral Therapy(SMART)Study Group, "CD4+ count-guided interruption of antiretroviral treatment", N Engl J Med, 355, pp.2283~2296 (2006)
27. Maggiolo F, "Efavirenz : a decade of clinical experience in the treatment of HIV", J Antimicrob Chemother, 64, pp.910~928 (2009)
28. Ford N, "Safety, efficacy, and pharmacokinetics of rilpivirine : systematic review with an emphasis on resource-limited settings", HIV AIDS(Auckl), 3, pp.35~44 (2011)
29. Colombier MA, "Doravirine : a review", Curr Opin HIV AIDS, 13, pp.308~314 (2018)
30. Vrouenraets SM, "Efavirenz : a review", Expert Opin Pharmacother, 8, pp.851~871 (2007)
31. Garvey L, "Rilpivirine : a novel non-nucleoside reverse transcriptase inhibitor", Expert Opin Investig Drugs, 18, pp.1035~1041 (2009)
32. Le Tiec C, "Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir", Clin Pharmacokinet, 44, pp.1035~1050 (2005)
33. Rittweger M, "Clinical pharmacokinetics of darunavir", Clin Pharmacokinet, 46, pp.739~756 (2007)
34. Shiomi M, "Effects of a protein-rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects : a randomized, three-way crossover study", J Clin Pharmacol, 54, pp.640~648 (2014)
35. San C, "Management of oral antiretroviral administration in patients with swallowing disorders or with an enteral feeding tube", Med Mal Infect, 50, pp.537~544 (2020)
36. Walker CK, "Antiretroviral therapy management in adults with HIV during ICU admission", J Pharm Pract, 35, pp.952~962 (2022)
37. Hocqueloux L, "Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy adults : the SOLUBIC randomized crossover study", J Antimicrob Chemother, 78, pp.161~168 (2022)
38. Roskam-Kwint M, "Crushing of dolutegravir fixed-dose combination tablets increases dolutegravir exposure", J Antimicrob Chemother, 73, pp.2430~2434 (2018)
39. Scholten S, "Administration of darunavir tablets in patients with difficulties in swallowing – two case reports", J Int AIDS Soc, 13(Suppl 4), pp.P114~ (2010)
40. Taegtmeyer AB, "Effect of continuous venovenous hemodiafiltration on darunavir and raltegravir exposure after administration via a gastroduodenal tube", AIDS, 25, pp.1339~1341 (2011)
41. Kim CH, "Orogastric administration of crushed darunavir tablets for a critically ill patient", Can J Hosp Pharm, 67, pp.39~42 (2014)
42. Brown K, "Impact of splitting or crushing on the relative bioavailability of the darunavir", cobicistat, tenofovir alafenamide single-tablet regimen, pp.Clin Pharmacol Drug Dev, 2019[DOI]
43. Porter AM, "Administration of crushed doravirine via nasojejunal feeding tube in a patient with treatment-experienced human immunodeficiency virus", J Pharm Pract, 36, pp.745~746 (2023)
44. Cattaneo D, "Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing", Antimicrob Agents Chemother, 56, pp.6132~6136 (2012)
45. Best BM, "Pharmacokinetics of lopinavir", ritonavir crushed versus whole tablets in children, 2011, pp.58, 385~391
46. Kakuda TN, "Single-dose pharmacokinetics of pediatric and adult formulations of etravirine and swallowability of the 200-mg tablet : results from three Phase 1 studies", Int J Clin Pharmacol Ther, 51, pp.725~737 (2013)
47. Lucas GM, "Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV : 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America", Clin Infect Dis, 59, pp.e96~e138 (2014)
48. Kim JH, "The incidence and risk factors of renal insufficiency among Korean HIV infected patients : the Korea HIV", AIDS cohort study, 2022, pp.54, 534~541
49. Srisopa S, "Incidence and risk factors of tenofovir disoproxil fumarate induced nephrotoxicity and renal function recovery, a hospital case-control study", Infect Chemother, 55, pp.226~236 (2023)
50. Böhler J, "Pharmacokinetic principles during continuous renal replacement therapy : drugs and dosage", Kidney Int Suppl, (72), pp.S24~S28 (1999)
51. Kim J, "Weight gain and lipid profile changes in Koreans with human immunodeficiency virus undergoing integrase strand transfer inhibitor-based regimens", Infect Chemother, 54, pp.419~432 (2022)
52. Chang HH, "Weight gain and metabolic syndrome in human immunodeficiency virus patients", Infect Chemother, 54, pp.220~235 (2022)
53. Steenackers N, "Adaptations in gastrointestinal physiology after sleeve gastrectomy and Roux-en-Y gastric bypass", Lancet Gastroenterol Hepatol, 6, pp.225~237 (2021)
54. Tomilo DL, "Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers", Pharmacotherapy, 26, pp.341~346 (2006)
55. James C, "Rilpivirine : a second-generation nonnucleoside reverse transcriptase inhibitor", Am J Health Syst Pharm, 69, pp.857~861 (2012)
56. Song I, "Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects", J Clin Pharmacol, 55, pp.490~496 (2015)
57. Tempestilli M, "Pharmacokinetics of bictegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV", J Antimicrob Chemother, 76, pp.3320~3322 (2021)
58. Piso RJ, "Dolutegravir plasma levels after gastric bypass surgery", AIDS, 31, pp.1052~1054 (2017)
59. MacBrayne CE, "Tenofovir, emtricitabine, and darunavir", ritonavir pharmacokinetics in an HIV-infected patient after Roux-en-Y gastric bypass surgery, 2014, pp.48, 816~819
60. Baettig V, "Boosted darunavir, emtricitabine and tenofovir pharmacokinetics in sthe early and late postgastric bypass surgery periods", AIDS, 32, pp.1903~1905 (2018)
61. Muzard L, "Tenofovir pharmacokinetic after sleeve-gastrectomy in four severely obese patients living with HIV", Obes Res Clin Pract, 11, pp.108~113 (2017)
62. Amouyal C, "Sleeve gastrectomy in morbidly obese HIV patients : focus on anti-retroviral treatment absorption after surgery", Obes Surg, 28, pp.2886~2893 (2018)
63. Roelofsen EE, "Pharmacokinetics of tenofovir disoproxyl fumarate", emtricitabine in a client on pre-exposure prophylaxis after a total gastrectomy, 2020, pp.34, 1989~1991
64. Hong WB, "Changes of drug pharmacokinetics in patients with short bowel syndrome : a systematic review", Eur J Drug Metab Pharmacokinet, 46, pp.465~478 (2021)
65. Severijnen R, "Enteral drug absorption in patients with short small bowel : a review", Clin Pharmacokinet, 43, pp.951~962 (2004)
66. Ikuma M, "Therapeutic drug monitoring of anti-human immunodeficiency virus drugs in a patient with short bowel syndrome", Intern Med, 55, pp.3059~3063 (2016)

관련 논문AI추천